Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 2. A summary of the clinical use of anti-angiogenic therapy. Anti VEGF neutralizing antibodies (Bevacizumab, Ranibizumab), VEGF165-neutralizing RNA aptamer (Pegaptanib), VEGFR1-R2 fusion peptide (VEGF-A-Trap) and VEGFR/multi TK inhibitors (Sorafenib, Sunitinib, etc.) were approved for clinical use. Bevacizumab and VEGFR/multi TK inhibitors are for the treatment of cancer. Others are for the treatment of AMD.
Biomol Ther (Seoul) 2014;22:1~9
© Biomolecules & Therapeutics